What are the risks of stroke/systemic thromboembolism when comparing rivaroxaban vs dabigatran?
A meta-analysis of real-world observational studies of dabigatran was consistent with findings from Randomized Evaluation of Long-term Anticoagulant Therapy with Dabigatran Etexilate (RE-LY). Compared with VKA, risk of stroke with dabigatran vs warfarin was Dabigatran was also associated with a lower risk of intracranial bleeding (HR, 0.45; 95% CI, 0.38-0.52) and lower risk of death (HR, 0.73; 95% CI, 0.61-0.87). One systematic review and meta-analysis provided comparative effectiveness and safety data for rivaroxaban vs dabigatran (n 3 trials), and the risks of stroke/ systemic thromboembolism with rivaroxaban were found to be similar compared with dabigatran.